Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MLN0002

 
National Institutes of Health

Related topics

Related topics

2 relations
LDP 02

Broader (1)

vedolizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Vedolizumab safety in pregnancy and newborn outcomes
We read with interest the study by Colombel et al 1 on vedolizumab (VDZ) safety in Crohn's disease (CD) and ulcerative colitis… Expand
Review
2015
Review
2015
Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
Crohn’s disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current approved biologic therapies are… Expand
  • table 1
Review
2015
Review
2015
Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited… Expand
  • table 1
  • table 2
  • table 3
Highly Cited
2012
Highly Cited
2012
Exclusive antagonism of the &agr;4&bgr;7 integrin by vedolizumab confirms the gut‐selectivity of this pathway in primates
Background: Biological therapies that antagonize specific molecules have demonstrated efficacy in inflammatory bowel diseases… Expand
  • table 1
  • table 1
  • figure 1
  • table 2
  • table 3
Review
2011
Review
2011
Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis
Crohn’s disease and ulcerative colitis are two chronic inflammatory bowel diseases. Current biologic therapies are limited to… Expand
  • table 1
  • table 2
  • figure 2
2010
2010
Veto on vedolizumab (MLN0002) for Crohn's disease.
  • D. Baumgart
  • Inflammatory bowel diseases
  • 2010
    • Corpus ID: 35402548
 
2009
2009
P164 - Clinical pharmacology of vedolizumab (MLN0002) in patients with active ulcerative colitis
 
2009
2009
P130 - Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to α4β7 integrin
 
Highly Cited
2008
Highly Cited
2008
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.
BACKGROUND & AIMS Selective blockade of lymphocyte-vascular endothelium interactions in the gastrointestinal tract is a promising… Expand
  • figure 1
2008
2008
Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to the alpha4beta7 integrin: P-0025.
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE